RU95109908A - PHARMACEUTICAL COMPOSITION - Google Patents
PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- RU95109908A RU95109908A RU95109908/14A RU95109908A RU95109908A RU 95109908 A RU95109908 A RU 95109908A RU 95109908/14 A RU95109908/14 A RU 95109908/14A RU 95109908 A RU95109908 A RU 95109908A RU 95109908 A RU95109908 A RU 95109908A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- polysorbate
- receptor antagonist
- polyoxyethylene
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 15
- 239000002736 nonionic surfactant Substances 0.000 claims 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- -1 sorbitol ester Chemical class 0.000 claims 6
- 102000019223 Interleukin-1 receptor family Human genes 0.000 claims 5
- 108050006617 Interleukin-1 receptor family Proteins 0.000 claims 5
- 239000002464 receptor antagonist Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 229950008882 Polysorbate Drugs 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 Polysorbate 80 Drugs 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 229920005682 EO-PO block copolymer Polymers 0.000 claims 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N Glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 claims 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 1
- 102100005027 IL1RN Human genes 0.000 claims 1
- 101710007852 IL1RN Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001451 Polypropylene glycol Polymers 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 1
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 1
- 229940043264 dodecyl sulfate Drugs 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000007981 phosphate-citrate buffer Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 1
- 239000001570 sorbitan monopalmitate Substances 0.000 claims 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000011778 trisodium citrate Substances 0.000 claims 1
Claims (14)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94700692A | 1992-09-17 | 1992-09-17 | |
US07/947006 | 1992-09-17 | ||
US07/947,006 | 1992-09-17 | ||
PCT/US1993/008802 WO1994006457A1 (en) | 1992-09-17 | 1993-09-17 | Pharmaceutical formulations of interleukin-1 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95109908A true RU95109908A (en) | 1997-12-10 |
RU2126262C1 RU2126262C1 (en) | 1999-02-20 |
Family
ID=25485348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95109908A RU2126262C1 (en) | 1992-09-17 | 1993-09-17 | Pharmaceutical composition |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0661992B1 (en) |
JP (1) | JP3626755B2 (en) |
KR (1) | KR950703358A (en) |
AT (1) | ATE257389T1 (en) |
AU (1) | AU675969B2 (en) |
CA (1) | CA2141953C (en) |
CZ (1) | CZ291261B6 (en) |
DE (1) | DE69333378T2 (en) |
DK (1) | DK0661992T3 (en) |
ES (1) | ES2213744T3 (en) |
FI (1) | FI951250A (en) |
HU (1) | HU219445B (en) |
NO (1) | NO321453B1 (en) |
NZ (1) | NZ256328A (en) |
PL (1) | PL175705B1 (en) |
PT (1) | PT661992E (en) |
RO (1) | RO113528B1 (en) |
RU (1) | RU2126262C1 (en) |
WO (1) | WO1994006457A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
ATE508733T1 (en) * | 1996-03-04 | 2011-05-15 | Penn State Res Found | MATERIALS AND METHODS FOR INCREASE CELLULAR INTERNALIZATION |
CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
ES2907826T3 (en) | 2001-06-26 | 2022-04-26 | Amgen Inc | Antibodies to OPGL |
JP4610154B2 (en) * | 2002-05-30 | 2011-01-12 | 大塚製薬株式会社 | Injectable preparation |
NZ605429A (en) | 2002-09-06 | 2014-08-29 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
US10765747B2 (en) * | 2004-04-02 | 2020-09-08 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
JP2008120722A (en) * | 2006-11-10 | 2008-05-29 | Benesis Corp | Placebo for use with biologic |
WO2009062339A1 (en) | 2007-11-14 | 2009-05-22 | General Regeneratives, Ltd. | Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
WO2009100406A2 (en) * | 2008-02-07 | 2009-08-13 | Synta Pharmaceuticals Corp. | Topical formulations for the treatment of psoriasis |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
CN101690801B (en) | 2009-10-26 | 2012-08-01 | 上海交通大学 | Application of interleukin-1 receptor antagonist and medicinal composition thereof |
JP2013510834A (en) | 2009-11-16 | 2013-03-28 | メリテク | [1,5] -diazocine derivatives |
HUE063115T2 (en) | 2010-07-29 | 2023-12-28 | Buzzard Pharmaceuticals AB | Chimeric il-1 receptor type i antagonists |
WO2012078101A1 (en) * | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
RU2599848C2 (en) * | 2011-02-11 | 2016-10-20 | Сведиш Орфан Биовитрум Аб (Пабл) | Citrate free pharmaceutical compositions comprising anakinra |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
CA2843197A1 (en) * | 2011-07-29 | 2013-02-07 | Eleven Biotherapeutics, Inc. | Purified proteins |
PL2968468T3 (en) | 2013-03-13 | 2021-12-20 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
CA3002786C (en) * | 2015-10-30 | 2021-09-07 | Bonac Corporation | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene |
WO2018022982A1 (en) | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5416568B2 (en) * | 1972-09-29 | 1979-06-23 | ||
JPS537491B2 (en) * | 1972-09-30 | 1978-03-18 | ||
AU9106491A (en) * | 1991-01-17 | 1992-08-27 | Upjohn Company, The | Method of preventing and treating insulin dependent diabetes mellitus |
-
1993
- 1993-09-17 CA CA002141953A patent/CA2141953C/en not_active Expired - Lifetime
- 1993-09-17 RU RU95109908A patent/RU2126262C1/en active
- 1993-09-17 DE DE69333378T patent/DE69333378T2/en not_active Expired - Lifetime
- 1993-09-17 DK DK93921651T patent/DK0661992T3/en active
- 1993-09-17 NZ NZ256328A patent/NZ256328A/en not_active IP Right Cessation
- 1993-09-17 CZ CZ1995643A patent/CZ291261B6/en not_active IP Right Cessation
- 1993-09-17 KR KR1019950701028A patent/KR950703358A/en not_active Application Discontinuation
- 1993-09-17 WO PCT/US1993/008802 patent/WO1994006457A1/en active IP Right Grant
- 1993-09-17 JP JP50833894A patent/JP3626755B2/en not_active Expired - Lifetime
- 1993-09-17 RO RO95-00540A patent/RO113528B1/en unknown
- 1993-09-17 HU HU9500790A patent/HU219445B/en unknown
- 1993-09-17 ES ES93921651T patent/ES2213744T3/en not_active Expired - Lifetime
- 1993-09-17 AT AT93921651T patent/ATE257389T1/en active
- 1993-09-17 PL PL93308543A patent/PL175705B1/en unknown
- 1993-09-17 AU AU49276/93A patent/AU675969B2/en not_active Expired
- 1993-09-17 PT PT93921651T patent/PT661992E/en unknown
- 1993-09-17 EP EP93921651A patent/EP0661992B1/en not_active Expired - Lifetime
-
1995
- 1995-03-15 NO NO19951006A patent/NO321453B1/en not_active IP Right Cessation
- 1995-03-16 FI FI951250A patent/FI951250A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95109908A (en) | PHARMACEUTICAL COMPOSITION | |
KR950703358A (en) | PHARMACEUTICAL FORMULATIONS OF INTEREUKIN-1 INHIBITORS | |
US5292502A (en) | Non-irritating dentifrice | |
JP3446214B2 (en) | Liquid transparent oral composition | |
AR015715A1 (en) | A HAIR CONDITIONING COMPOSITION | |
RU99100327A (en) | SURFACE-ACTIVE SYSTEM FOR STIMULATION OF ANTIBACTERIAL ABSORPTION ON DENTIN | |
CA2284000A1 (en) | Hydrophilic binary systems for the administration of cyclosporine | |
MX9305535A (en) | COMPOSITIONS AND CONCENTRATES GERMICIDES BASED ON IODINE-DETERGENT, WATER AND STABLE. | |
JP2002255771A (en) | Liquid composition for oral cavity not mixed with alcohol | |
EE05533B1 (en) | Pharmaceutical composition and preparation containing micronized drospirenone and 'strogen and their use | |
JPH0747531B2 (en) | Oral composition | |
RU99113343A (en) | MEDICINAL FORMS OF CYCLOSPORIN FOR ORAL ADMINISTRATION | |
DE69736739D1 (en) | Stabilized growth hormone preparation and method for its preparation | |
JP2002537242A5 (en) | ||
JPS56110612A (en) | Readily disintegrable and absorbable compression molded article of slightly soluble drug | |
TW327602B (en) | A pharmaceutical composition of an ophthalmic suspension containing difluprednate | |
KR840005020A (en) | Corticosteroid external preparations | |
FR2665155B1 (en) | BASIC ANTISUDORAL BASIC ALUMINUM ACTIVE COMPOUNDS, ANTISUDORAL COMPOSITIONS CONTAINING SUCH INGREDIENTS, AND METHODS OF PREPARING SUCH PRODUCTS AND COMPOSITIONS. | |
DE69101152D1 (en) | Poly (alpha-hydroxy acrylic acid) and derivatives as anti-tartar active ingredients in oral compositions. | |
AR007549A1 (en) | COMPOSITION OF SOAP OF FATTY ACIDS IN BARS CONTAINING SYNTHETIC SURFACTANTS | |
IT1249696B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING FURAN DERIVATIVES AND PROCEDURE TO PREPARE THEM. | |
DE3773440D1 (en) | PHARMACEUTICAL COMPOSITIONS FOR SUPPOSITORIES. | |
DE69205839D1 (en) | Dermatological and cosmetic composition. | |
RU99114019A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES N-SULFONILINDOLINE | |
RU97107154A (en) | WATER COMPOSITIONS CONTAINING CYPROFLOXACIN, THEIR APPLICATION AND METHOD FOR PRODUCING |